Sub B10

16. (New) An isolated protein having heparanase (endo-β-D-glucuronidase) catalytic activity or being cleavable so as to acquire said heparanase catalytic activity, said isolated protein being substantially devoid of glycosilation.

17. (New) A pharmaceutical composition comprising, as an active ingredient, the isolated protein of claim 16, and a pharmaceutically acceptable carrier.

Sub B11

18. (New) A preparation comprising a protein having heparanase (endo-β-D-glucuronidase) catalytic activity or being cleavable so as to acquire said heparanase catalytic activity, the preparation being substantially free of a CXC chemokine or PAI1.

A1 Cont

19. (New) A pharmaceutical composition comprising, as an active ingredient, the preparation of claim 18, and a pharmaceutically acceptable carrier.

Sub B12

20. (New) An isolated protein having heparanase (endo-β-D-glucuronidase) catalytic activity or being cleavable so as to acquire said heparanase catalytic activity, said isolated protein being characterized by insect cell derived sugar prosthetic groups.

21. (New) A pharmaceutical composition comprising, as an active ingredient, the isolated protein of claim 20, and a pharmaceutically acceptable carrier.

Sub B13

22. (New) An isolated protein having heparanase catalytic (endo-β-D-glucuronidase) activity or being cleavable so as to acquire said heparanase catalytic

activity, said isolated protein being characterized by non-human cell derived sugar prosthetic groups.

23. (New) A pharmaceutical composition comprising, as an active ingredient, the isolated protein of claim 22, and a pharmaceutically acceptable carrier.

24. (New) A preparation comprising a protein of about 50 or about 65 kDa as determined by a denaturing polyacrylamide gel electrophoresis, said protein having heparanase (endo-β-D-glucuronidase) catalytic activity or being cleavable so as to acquire said heparanase catalytic activity, respectively, the preparation being free of non-heparanase polypeptides encoded by human nucleic acid sequences.

25. (New) A pharmaceutical composition comprising, as an active ingredient, the preparation of claim 24, and a pharmaceutically acceptable carrier.

26. (New) An isolated protein of about 50 or about 65 kDa as determined by a denaturing polyacrylamide gel electrophoresis, said protein having heparanase (endo-β-D-glucuronidase) catalytic activity or being cleavable so as to acquire said heparanase catalytic activity, respectively, said isolated protein being substantially devoid of glycosilation.

27. (New) A pharmaceutical composition comprising, as an active ingredient, the isolated protein of claim 26, and a pharmaceutically acceptable carrier.

Sub B16

28. (New) A preparation comprising a protein of about 50 or about 65 kDa as determined by a denaturing polyacrylamide gel electrophoresis, said protein having heparanase (endo-β-D-glucuronidase) catalytic activity or being cleavable so as to acquire said heparanase catalytic activity, respectively, the preparation being substantially free of a CXC chemokine or PAI1.

29. (New) A pharmaceutical composition comprising, as an active ingredient, the preparation of claim 28, and a pharmaceutically acceptable carrier.

Sub B17

A1 Cont

30. (New) An isolated protein of about 50 or about 65 kDa as determined by a denaturing polyacrylamide gel electrophoresis, said protein having heparanase (endo-β-D-glucuronidase) catalytic activity or being cleavable so as to acquire said heparanase catalytic activity, respectively, said isolated protein being characterized by insect cell derived sugar prosthetic groups.

31. (New) A pharmaceutical composition comprising, as an active ingredient, the isolated protein of claim 30, and a pharmaceutically acceptable carrier.

Sub B18

32. (New) An isolated protein of about 50 or about 65 kDa as determined by a denaturing polyacrylamide gel electrophoresis, said protein having heparanase (endo-β-D-glucuronidase) catalytic activity or being cleavable so as to acquire said heparanase catalytic activity, respectively, said isolated protein being characterized by non-human cell derived sugar prosthetic groups.

33. (New) A pharmaceutical composition comprising, as an active ingredient, the isolated protein of claim 32, and a pharmaceutically acceptable carrier.

34. (New) A preparation comprising a protein at least 70 % homologous to SEQ ID NO:10, 14 or 44, said protein having heparanase (endo-β-D-glucuronidase) catalytic activity or being cleavable so as to acquire said heparanase catalytic activity, the preparation being free of non-heparanase polypeptides encoded by human nucleic acid sequences.

35. (New) A pharmaceutical composition comprising, as an active ingredient, the preparation of claim 34, and a pharmaceutically acceptable carrier.

36. (New) An isolated protein at least 70 % homologous to SEQ ID NO:10, 14 or 44, the protein having heparanase (endo-β-D-glucuronidase) catalytic activity or being cleavable so as to acquire said heparanase catalytic activity, said isolated protein being substantially devoid of glycosilation.

A1 cm.t

37. (New) A pharmaceutical composition comprising, as an active ingredient, the isolated protein of claim 36, and a pharmaceutically acceptable carrier.

38. (New) A preparation comprising a protein at least 70 % homologous to SEQ ID NO:10, 14 or 44, said protein having heparanase (endo-β-D-glucuronidase) catalytic activity or being cleavable so as to acquire said heparanase catalytic activity, the preparation being substantially free of a CXC chemokine or PAI1.

39. (New) A pharmaceutical composition comprising, as an active ingredient, the preparation of claim 38, and a pharmaceutically acceptable carrier.

40. (New) An isolated protein at least 70 % homologous to SEQ ID NO:10, 14 or 44, the protein having heparanase (endo-β-D-glucuronidase) catalytic activity or being cleavable so as to acquire said heparanase catalytic activity, said isolated protein being characterized by insect cell derived sugar prosthetic groups.

41. (New) A pharmaceutical composition comprising, as an active ingredient, the isolated protein of claim 40, and a pharmaceutically acceptable carrier.

A1 Cont

42. (New) An isolated protein at least 70 % homologous to SEQ ID NO:10, 14 or 44, the protein having heparanase catalytic (endo-β-D-glucuronidase) activity or being cleavable so as to acquire said heparanase catalytic activity, said isolated protein being characterized by non-human cell derived sugar prosthetic groups.

43. (New) A pharmaceutical composition comprising, as an active ingredient, the isolated protein of claim 42, and a pharmaceutically acceptable carrier.

Rule 47

44. (New) A preparation comprising a protein having a pair of glutamic acids participating in its active site and having heparanase (endo-β-D-glucuronidase) catalytic activity or being cleavable so as to acquire said heparanase catalytic activity, the preparation being free of non-heparanase polypeptides encoded by human nucleic acid sequences.

45. (New) A pharmaceutical composition comprising, as an active ingredient, the preparation of claim 44, and a pharmaceutically acceptable carrier.

46. (New) An isolated protein having a pair of glutamic acids participating in its active site and having heparanase (endo-β-D-glucuronidase) catalytic activity or being cleavable so as to acquire said heparanase catalytic activity, said isolated protein being substantially devoid of glycosilation.

47. (New) A pharmaceutical composition comprising, as an active ingredient, the isolated protein of claim 46, and a pharmaceutically acceptable carrier.

48. (New) A preparation comprising a protein having a pair of glutamic acids participating in its active site and having heparanase (endo-β-D-glucuronidase) catalytic activity or being cleavable so as to acquire said heparanase catalytic activity, the preparation being substantially free of a CXC chemokine or PAI1.

49. (New) A pharmaceutical composition comprising, as an active ingredient, the preparation of claim 48, and a pharmaceutically acceptable carrier.

50. (New) An isolated protein having a pair of glutamic acids participating in its active site and heparanase (endo-β-D-glucuronidase) catalytic activity or being cleavable so as to acquire said heparanase catalytic activity, said isolated protein being characterized by insect cell derived sugar prosthetic groups.

51. (New) A pharmaceutical composition comprising, as an active ingredient, the isolated protein of claim 50, and a pharmaceutically acceptable carrier.

52. (New) An isolated protein having a pair of glutamic acids participating in its active site and having heparanase catalytic (endo-β-D-glucuronidase) activity or being cleavable so as to acquire said heparanase catalytic activity, said isolated protein being characterized by non-human cell derived sugar prosthetic groups.

53. (New) A pharmaceutical composition comprising, as an active ingredient, the isolated protein of claim 52, and a pharmaceutically acceptable carrier.

54. (New) A preparation comprising a protein having heparanase (endo-β-D-glucuronidase) catalytic activity or being cleavable so as to acquire said heparanase catalytic activity, said protein being capable of eliciting an anti-heparanase antibody, the preparation being free of non-heparanase polypeptides encoded by human nucleic acid sequences.

55. (New) A pharmaceutical composition comprising, as an active ingredient, the preparation of claim 54, and a pharmaceutically acceptable carrier.

56. (New) An isolated protein having heparanase (endo-β-D-glucuronidase) catalytic activity or being cleavable so as to acquire said heparanase catalytic activity, said protein being capable of eliciting an anti-heparanase antibody, said isolated protein being substantially devoid of glycosilation.

57. (New) A pharmaceutical composition comprising, as an active ingredient, the isolated protein of claim 56, and a pharmaceutically acceptable carrier.

58. (New) A preparation comprising a protein having heparanase (endo-β-D-glucuronidase) catalytic activity or being cleavable so as to acquire said heparanase catalytic activity, said protein being capable of eliciting an anti-heparanase antibody, the preparation being substantially free of a CXC chemokine or PAI1.

59. (New) A pharmaceutical composition comprising, as an active ingredient, the preparation of claim 58, and a pharmaceutically acceptable carrier.

60. (New) An isolated protein having heparanase (endo-β-D-glucuronidase) catalytic activity or being cleavable so as to acquire said heparanase catalytic activity, said protein being capable of eliciting an anti-heparanase antibody, said isolated protein being characterized by insect cell derived sugar prosthetic groups.

61. (New) A pharmaceutical composition comprising, as an active ingredient, the isolated protein of claim 60, and a pharmaceutically acceptable carrier.

62. (New) An isolated protein having heparanase catalytic (endo-β-D-glucuronidase) activity or being cleavable so as to acquire said heparanase catalytic activity, said protein being capable of eliciting an anti-heparanase antibody, said isolated protein being characterized by non-human cell derived sugar prosthetic groups.

63. (New) A pharmaceutical composition comprising, as an active ingredient, the isolated protein of claim 62, and a pharmaceutically acceptable carrier.